{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:01:12Z","timestamp":1778904072703,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T00:00:00Z","timestamp":1710460800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ijid.2024.107014","type":"journal-article","created":{"date-parts":[[2024,3,16]],"date-time":"2024-03-16T16:28:51Z","timestamp":1710606531000},"page":"107014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Next-generation vaccines for tropical infectious diseases"],"prefix":"10.1016","volume":"143","author":[{"given":"Tammy","family":"Allen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8181-6321","authenticated-orcid":false,"given":"Maria Eugenia","family":"Castellanos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Giacomin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3985-1817","authenticated-orcid":false,"given":"Nadira D.","family":"Karunaweera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9259-7873","authenticated-orcid":false,"given":"Andreas","family":"Kupz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Carlos","family":"Lol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dileep","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suchandan","family":"Sikder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bemnet","family":"Tedla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"van Eijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7894-9625","authenticated-orcid":false,"given":"Danica","family":"Vojisavljevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangzu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1571-3997","authenticated-orcid":false,"given":"Saparna","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2024.107014_bib0001","series-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030","year":"2020"},{"key":"10.1016\/j.ijid.2024.107014_bib0002","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005037","article-title":"Benchmarking the cost per person of mass treatment for selected neglected tropical diseases: an approach based on literature review and meta-regression with web-based software application","volume":"10","author":"Fitzpatrick","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.ijid.2024.107014_bib0003","series-title":"Word malaria report 2021","year":"2021"},{"key":"10.1016\/j.ijid.2024.107014_bib0004","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.pt.2020.03.009","article-title":"Plasmodium vivax in the era of the shrinking P. falciparum map","volume":"36","author":"Price","year":"2020","journal-title":"Trends Parasitol"},{"key":"10.1016\/j.ijid.2024.107014_bib0005","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1093\/cid\/ciy001","article-title":"Are we on our way to achieving the 2020 goals for schistosomiasis morbidity control using current World Health Organization guidelines?","volume":"66","author":"Toor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2024.107014_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112304","article-title":"Targets and strategies for vaccine development against dengue viruses","volume":"144","author":"Wang","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ijid.2024.107014_bib0007","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001831","article-title":"Challenges on the development of a dengue vaccine: a comprehensive review of the state of the art","volume":"104","author":"Pintado Silva","year":"2023","journal-title":"J Gen Virol"},{"key":"10.1016\/j.ijid.2024.107014_bib0008","doi-asserted-by":"crossref","first-page":"7229","DOI":"10.1016\/j.vaccine.2011.06.094","article-title":"From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine","volume":"29","author":"Guy","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2024.107014_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1089\/vim.2006.19.10","article-title":"Development of a live attenuated dengue virus vaccine using reverse genetics","volume":"19","author":"Blaney","year":"2006","journal-title":"Viral Immunol"},{"key":"10.1016\/j.ijid.2024.107014_bib0010","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S1473-3099(20)30023-2","article-title":"Safety and immunogenicity of the tetravalent, live-attenuated dengue vaccine Butantan-DV in adults in Brazil: a two-step, double-blind, randomised placebo-controlled phase 2 trial","volume":"20","author":"Kallas","year":"2020","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2024.107014_bib0011","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(20)30414-1","article-title":"Efficacy of a tetravalent dengue vaccine in healthy children aged 4\u201316 years: a randomised, placebo-controlled, phase 3 trial","volume":"395","author":"Biswal","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2024.107014_bib0012","series-title":"Takeda's Dengue Vaccine Candidate Provides Continued Protection Against Dengue Fever Through 4.5 Years in Pivotal Clinical Trial","year":"2022"},{"key":"10.1016\/j.ijid.2024.107014_sbref0013","series-title":"COVID-19 pandemic fuels largest continued backslide in vaccinations in three decades","year":"2022"},{"key":"10.1016\/j.ijid.2024.107014_bib0014","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.vaccine.2005.07.091","article-title":"Vaccination with irradiated Ancylostoma caninum third stage larvae induces a Th2 protective response in dogs","volume":"24","author":"Fujiwara","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2024.107014_bib0015","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/S1473-3099(21)00153-5","article-title":"Vaccination of human participants with attenuated Necator americanus hookworm larvae and human challenge in Australia: a dose-finding study and randomised, placebo-controlled, phase 1 trial","volume":"21","author":"Chapman","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2024.107014_bib0016","doi-asserted-by":"crossref","first-page":"e1024","DOI":"10.1016\/S2666-5247(23)00218-5","article-title":"Protective efficacy of short-term infection with Necator americanus hookworm larvae in healthy volunteers in the Netherlands: a single-centre, placebo-controlled, randomised, controlled, phase 1 trial","volume":"4","author":"Hoogerwerf","year":"2023","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.ijid.2024.107014_bib0017","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jaci.2012.04.027","article-title":"Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths","volume":"130","author":"Diemert","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.ijid.2024.107014_bib0018","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1473-3099(20)30288-7","article-title":"Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial","volume":"21","author":"Adegnika","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2024.107014_bib0019","doi-asserted-by":"crossref","DOI":"10.1074\/mcp.M111.007948","article-title":"Sterile protective immunity to malaria is associated with a panel of novel P. falciparum antigens","volume":"10","author":"Trieu","year":"2011","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ijid.2024.107014_bib0020","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/vaccines9070740","article-title":"Monoclonal antibodies targeting an Opisthorchis viverrini extracellular vesicle tetraspanin protect hamsters against challenge infection","volume":"9","author":"Phumrattanaprapin","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ijid.2024.107014_bib0021","series-title":"Malaria Vaccine Funders Group. Malaria vaccine technology roadmap","year":"2013"},{"key":"10.1016\/j.ijid.2024.107014_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.parint.2022.102592","article-title":"Potential role of vaccines in elimination of Plasmodium vivax","volume":"90","author":"White","year":"2022","journal-title":"Parasitol Int"},{"key":"10.1016\/j.ijid.2024.107014_bib0023","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","article-title":"Malaria vaccines since 2000: progress, priorities, products","volume":"5","author":"Duffy","year":"2020","journal-title":"npj Vaccines"},{"key":"10.1016\/j.ijid.2024.107014_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","article-title":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2024.107014_bib0025","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(21)00943-0","article-title":"Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial","volume":"397","author":"Datoo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2024.107014_bib0026","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41467-022-29226-3","article-title":"Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine","volume":"13","author":"Ar\u00e9valo-Herrera","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ijid.2024.107014_bib0027","doi-asserted-by":"crossref","first-page":"e28673","DOI":"10.7554\/eLife.28673","article-title":"Identification of highly-protective combinations of Plasmodium vivax recombinant proteins for vaccine development","volume":"6","author":"Fran\u00e7a","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.ijid.2024.107014_sbref0028","series-title":"United States National Library of Medicine","year":"2023"},{"key":"10.1016\/j.ijid.2024.107014_bib0029","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14760584.2019.1674145","article-title":"Malaria transmission-blocking vaccines: wheat germ cell-free technology can accelerate vaccine development","volume":"18","author":"Miura","year":"2019","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ijid.2024.107014_bib0030","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1080\/1040841X.2016.1249335","article-title":"Vi capsular polysaccharide: Synthesis, virulence, and application","volume":"43","author":"Hu","year":"2017","journal-title":"Crit Rev Microbiol"},{"key":"10.1016\/j.ijid.2024.107014_bib0031","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1093\/cid\/ciaa504","article-title":"Review on the recent advances on typhoid vaccine development and challenges ahead","volume":"71","author":"Syed","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2024.107014_bib0032","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2043103","volume":"18","author":"Thuluva","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.ijid.2024.107014_bib0033","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1016\/j.vaccine.2021.07.073","article-title":"Persisting antibody responses to Vi polysaccharide\u2013tetanus toxoid conjugate (Typbar TCV\u00ae) vaccine up to 7 years following primary vaccination of children < 2 years of age with, or without, a booster vaccination","volume":"39","author":"Vadrevu","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2024.107014_bib0034","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1016\/S0140-6736(17)32149-9","article-title":"Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial","volume":"390","author":"Jin","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijid.2024.107014_bib0035","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nm1430","article-title":"Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis","volume":"12","author":"Tran","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.ijid.2024.107014_bib0036","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1007\/s00436-009-1646-z","article-title":"Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine","volume":"105","author":"Ahmad","year":"2009","journal-title":"Parasitol Res"},{"key":"10.1016\/j.ijid.2024.107014_bib0037","doi-asserted-by":"crossref","DOI":"10.3389\/fitd.2021.719369","article-title":"Recent advances and methodological considerations on vaccine candidates for human schistosomiasis","volume":"2","author":"Panzner","year":"2021","journal-title":"Front Trop Dis"},{"key":"10.1016\/j.ijid.2024.107014_bib0038","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.1016\/j.vaccine.2019.08.075","article-title":"A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area","volume":"37","author":"Keitel","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.ijid.2024.107014_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004033","article-title":"An immunomics approach to schistosome antigen discovery: antibody signatures of naturally resistant and chronically infected individuals from endemic areas","volume":"10","author":"Gaze","year":"2014","journal-title":"PLoS Pathog"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224000857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971224000857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T07:01:16Z","timestamp":1715756476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971224000857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":39,"alternative-id":["S1201971224000857"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107014","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation vaccines for tropical infectious diseases","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2024.107014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"107014"}}